S. Martino

发表

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

E. Mardis, C. Perou, M. Ellis, 2016, npj Breast Cancer.

The influence of margin width on local control of ductal carcinoma in situ of the breast.

S. Martino, M. Silverstein, M. Lagios, 1999, The New England journal of medicine.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

D. Berry, E. Winer, E. Perez, 2006, JAMA.

Prediction of breast tumor progression by integrity of free circulating DNA in serum.

A. Giuliano, S. Martino, D. Hoon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer

G. Hortobagyi, S. Martino, A. Buzdar, 2000, Clinical transplantation.

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Clinical Cancer Research.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Peter A Kaufman, James N Ingle, Edith A Perez, 2002, Journal of the National Cancer Institute.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of piroxantrone in metastatic breast cancer

S. Martino, J. Doroshow, P. Ravdin, 1994, Investigational New Drugs.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Robert B Livingston, Dongsheng Tu, Jeffrey S Abrams, 2005, Journal of the National Cancer Institute.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

E. Perez, S. Martino, G. Sledge, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.

S. Martino, B. Redman, M. Simon, 1992, Journal of immunotherapy.

Weekly paclitaxel in the adjuvant treatment of breast cancer.

E. Perez, S. Martino, G. Sledge, 2008, The New England journal of medicine.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

J. Forbes, R. Gelber, G. Hortobagyi, 2015, The New England journal of medicine.

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

E. Perez, M. Piccart, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

C. Hudis, S. Martino, A. Wolff, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

E. Perez, M. Piccart, S. Martino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, E. Perez, 2014, The New England journal of medicine.

Adjuvant ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, The New England journal of medicine.

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

E. Perez, M. Piccart, S. Martino, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

E. Winer, R. Gelber, S. Martino, 2018, The New England journal of medicine.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

J. Forbes, R. Gelber, G. Hortobagyi, 2015, The New England journal of medicine.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

S. Cummings, T. Powles, J. Cauley, 2004, Journal of the National Cancer Institute.

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

S. Martino, R. Elledge, G. Clark, 2000, International journal of cancer.

Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.

S. Martino, R. Livingston, W. Barlow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, D. Visscher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

S. Lippman, S. Martino, C. Moinpour, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study

C. Osborne, S. Martino, C. Geyer, 1998, Breast Cancer Research and Treatment.

Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.

E. Perez, T. Whelan, S. Martino, 2009 .

Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.

J. Crowley, C. Coltman, S. Martino, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.

E. Perez, S. Martino, J. Ingle, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trends in the diagnosis of in situ breast cancer in the Detroit metropolitan area, 1973 to 1987

S. Martino, G. Swanson, M. Simon, 1992, Cancer.

Efficacy of radiotherapy for ovarian ablation

R. Gray, S. Martino, N. Robert, 2004, Cancer.

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

S. Cummings, T. Powles, J. Cauley, 2005 .

c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831.

E. Perez, S. Martino, N. Davidson, 2009 .

Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial

B. Gersh, E. Perez, A. Jaffe, 2005 .

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

E. Perez, S. Martino, J. Sparano, 2005 .

Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer

E. Perez, S. Martino, N. Wolmark, 2007 .

Levels of 5‐hydroxymethyl‐2′‐deoxyuridine in DNA from blood as a marker of breast cancer

S. Martino, P. LoRusso, M. Simon, 1996, Cancer.

Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.

Ji-Yeob Choi, Robert B Livingston, Li Tang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Breast Cancer Research and Treatment.

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

S. Martino, C. Geyer, G. Lyman, 2004, Breast Cancer Research and Treatment.

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.

C. Osborne, C. Coltman, S. Martino, 1991, Journal of the National Cancer Institute.

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

C. Osborne, S. Martino, R. Elledge, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.

S. Martino, C. Osborne, L. Hutchins, 1994, Cancer research.

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.

S. Martino, N. Robert, J. Ingle, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

E. Perez, R. Gelber, S. Martino, 2014, Journal of Clinical Oncology.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Peter A Kaufman, James N Ingle, Edith A Perez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Jong-Hyeon Jeong, Peter A Kaufman, Norman Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.

S. Martino, G. Sledge, L. Harris, 2011 .

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

hsp7O: Lack of Correlation with Response to Tamoxifen and Clinical Course of Disease in Estrogen Receptor-positive Metastatic Breast Cancer (A Southwest Oncology Group Study)’

S. Martino, R. Elledge, G. Clark, 2005 .

SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with >=4 involved axillary lymph nodes

G. Hortobagyi, C. Hudis, S. Martino, 2005 .

PATIENTS AND METHODS

D. Neuberg, S. Martino, G. Sledge, 1982 .

Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.

E. Perez, S. Martino, G. Sledge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199

E. Perez, S. Martino, G. Sledge, 2007 .

GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.

R. Gray, S. Martino, G. Sledge, 2009 .

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer

E. Perez, A. Jaffe, S. Martino, 2007 .

Abstract S2-1: Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer

S. Martino, G. Sledge, A. Wolff, 2010 .

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.

S. Martino, B. Redman, A. Al-Katib, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast‐Conserving Therapy with Adjuvant Paclitaxel and Radiation Therapy: Feasibility of Concurrent Treatment

S. Martino, L. Botnick, M. Tao, 2003, The breast journal.

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).

C. Osborne, S. Martino, R. Elledge, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, R. Gonzalez, 1993, Cancer.

Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

E. Mardis, C. Perou, E. Winer, 2012 .

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study.

S. Martino, R. Livingston, J. Paradelo, 1999, American Journal of Clinical Oncology.

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.

S. Martino, P. LoRusso, N. Ramnath, 1997, American journal of clinical oncology.

HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

C. Osborne, S. Martino, R. Elledge, 2004, Clinical Cancer Research.

A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.

S. Martino, H. Muss, S. Rudnick, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Molin Wang, George W. Sledge, Antonio C. Wolff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

E. Perez, S. Martino, G. Sledge, 2012, Journal of the National Cancer Institute.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

E. Perez, S. Martino, G. Sledge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

E. Perez, S. Martino, G. Sledge, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group

G. T. Budd, R. Gray, S. Martino, 2011, Medical Oncology.

An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology

S. Martino, M. Simon, Mohamed A. Hussein, 1993, Breast Cancer Research and Treatment.

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

R. Gelber, G. Hortobagyi, L. Minasian, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.

T. Whelan, S. Martino, N. Robert, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.

C. Osborne, S. Martino, P. Ravdin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

D. Neuberg, S. Martino, G. Sledge, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

S. Cummings, J. Cauley, S. Martino, 2006, Clinical Cancer Research.

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.

S. Martino, J. Ingle, J. Glick, 2000, The New England journal of medicine.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

H. Linden, S. Martino, C. Shapiro, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

S. Martino, C. Osborne, N. Davidson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil, vincristine, and prednisone compared with single‐agent L‐phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes

S. Martino, C. Osborne, S. Green, 2003, Cancer.

Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry: An Eastern Cooperative Oncology Group Study (2192)

S. Martino, N. Robert, L. Dressler, 2001, American journal of clinical oncology.

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.

S. Martino, C. Osborne, C. Russell, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.

S. Martino, S. Green, R. Hahn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

E. Perez, M. Piccart, S. Martino, 2004, The New England journal of medicine.

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

E. Perez, M. Piccart, S. Martino, 2003 .

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

E. Perez, G. Hortobagyi, S. Martino, 2009, Breast Cancer Research and Treatment.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Jong-Hyeon Jeong, Norman Wolmark, Priya Rastogi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 )

D. Berry, M. Ellis, E. Winer, 2011 .

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

E. Perez, T. Whelan, S. Martino, 2013 .

Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer.

J L Pater, M. Piccart, S. Martino, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

S. Martino, R. Elledge, D. Allred, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

R. Gray, E. Perez, S. Martino, 2012, Breast Cancer Research and Treatment.

Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen.

T. Whelan, S. Martino, N. Robert, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

S. Martino, N. Robert, D. Cella, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer

E. Perez, S. Martino, G. Sledge, 2012, Cancer.

A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, L. Heilbrun, 1990, Cancer.

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

D. Berry, E. Winer, E. Perez, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer two dose schedules

S. Martino, V. Vaitkevicius, A. Singhakowinta, 2004, Journal of Cancer Research and Clinical Oncology.

Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.

S. Martino, B. Samal, M. al-Sarraf, 1980, Cancer treatment reports.

Racial differences in cancer of the male breast — 15 year experience in the Detroit Metropolitan Area

S. Martino, G. Swanson, M. Simon, 2005, Breast Cancer Research and Treatment.

PCNU in advanced breast cancer.

S. Martino, A. Singhakowinta, B. Samal, 1983, Cancer treatment reports.

Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy

S. Martino, V. Vaitkevicius, S. Brooks, 1980, Cancer.

Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon

S. Martino, Y. Sohn, S. Rudnick, 2004, Journal of Cancer Research and Clinical Oncology.

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

R. Gelber, S. Martino, A. Goldhirsch, 2018 .

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011 .

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials.

S. Martino, J. Ingle, C. Osborne, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of a low-fat dietary intervention in women at high risk for breast cancer.

S. Martino, M. Simon, F. Valeriote, 1997, Nutrition and cancer.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

T. Powles, S. Martino, J. Costantino, 2004, The oncologist.

Dietary and anthropometric determinants of plasma lipoproteins during a long-term low-fat diet in healthy women.

S. Martino, L. Heilbrun, B. Reading, 1993, The American journal of clinical nutrition.

Effects of a low-fat diet on levels of oxidative damage to DNA to human peripheral nucleated blood cells.

S. Martino, Z. Djuric, F. Valeriote, 1991, Journal of the National Cancer Institute.

Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, S. Dakhil, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast.

S. Martino, M. Silverstein, M. Lagios, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

E. Perez, S. Martino, T. Pisansky, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

E. Winer, B. Gersh, E. Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

R. Gray, E. Perez, S. Martino, 2009, Clinical Cancer Research.

Reply to J.M. Guinebretiere and L. Arnould et al

E. Perez, S. Martino, G. Sledge, 2009 .

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

E. Perez, S. Martino, G. Sledge, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831

E. Perez, S. Martino, G. Sledge, 2013 .

Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence.

S. Lippman, S. Martino, C. Gotay, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975–1988)

S. Martino, G. Swanson, M. Simon, 1993, Cancer.

Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study.

R. Elashoff, S. Martino, R. Jeffery, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats, vegetables, and fruits.

S. Martino, S. Lababidi, Z. Djuric, 1998, Journal of the American Dietetic Association.

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.

B. Gersh, E. Perez, A. Jaffe, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

E. Perez, M. Piccart, S. Martino, 2006, Breast Cancer Research and Treatment.

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

E. Perez, T. Whelan, S. Martino, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

S. Martino, R. Livingston, W. Barlow, 2009, Clinical Cancer Research.

HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344.

S. Martino, L. Dressler, D. Weaver, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

E. Winer, R. Gelber, S. Loi, 2022, Cancer Research.

Dietary modulation of oxidative DNA damage.

S. Martino, Z. Djuric, L. Heilbrun, 1994, Advances in experimental medicine and biology.

Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy.

S. Martino, G. Sledge, A. Wolff, 2009 .

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

S. Martino, C. Moinpour, P. Ganz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

P. Neven, S. Loi, S. Nik-Zainal, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer

S. Martino, B. Redman, A. Wozniak, 1991, Cancer.

Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study

E. Perez, S. Martino, T. Pisansky, 2006 .

Safety assessment of raloxifene over eight years in a clinical trial setting*

S. Martino, S. Dowsett, J. Mershon, 2005, Current medical research and opinion.

Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial.

E. Perez, S. Martino, G. Sledge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831.

E. Perez, S. Martino, G. Sledge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Dongsheng Tu, Martine J Piccart, James N Ingle, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study

E. Perez, S. Martino, T. Pisansky, 2020, Cancer.

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

D. Berry, E. Mardis, M. Ellis, 2015, Journal of the National Cancer Institute.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

J. Forbes, R. Gelber, G. Hortobagyi, 2018, Journal of the National Cancer Institute.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

G. Hortobagyi, Qianqian Zhu, Song Liu, 2019, Clinical breast cancer.

Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626

S. Martino, R. Livingston, P. Ganz, 2001 .

413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741

D. Berry, E. Winer, C. Hudis, 2012 .

Reply to N. Magné et al

E. Perez, S. Martino, T. Pisansky, 2009 .

Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet !

Barbara L. Smith, D. Berry, E. Winer, 2003 .

Interrupted pregnancy as an indicator of poor prognosis in T1, 2, N0, M0 primary breast cancer

S. Martino, J. Russo, M. Brennan, 2005, Breast Cancer Research and Treatment.

Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831

E. Perez, S. Martino, N. Davidson, 2008 .

P2-12-02: Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial.

S. Martino, K. Ballman, N. Davidson, 2011 .

Serum interleukin 2 (IL-2) levels and prolactin bioactive/radioimmunoassay ratios of women at risk for breast cancer.

S. Martino, M. Alonso, C. Kresge, 1989, European journal of cancer & clinical oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

R. Gray, S. Martino, G. Sledge, 2013 .

Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer

E. Perez, S. Martino, G. Sledge, 2015 .

Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma

S. Martino, D. Decker, H. Hynes, 1987, Investigational new drugs.

Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women

S. Martino, O. Olevsky, 2008, Menopause.

Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer

A. Giuliano, S. Martino, P. Ray, 2012, Annals of Surgical Oncology.

Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer

E. Perez, S. Martino, G. Sledge, 2012, Cancer.

E. Perez, S. Martino, J. Sparano, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

E. Perez, S. Martino, G. Sledge, 2013, Clinical Cancer Research.

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Clinical Cancer Research.

E. Perez, S. Martino, G. Sledge, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

S. Cummings, J. Cauley, S. Martino, 2006, Clinical Cancer Research.

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

Reversible cardiac arrhythmia in a breast cancer patient treated with recombinant alpha interferon

S. Martino, Y. Sohn, B. Samal, 2005, Breast Cancer Research and Treatment.

Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

E. Winer, S. Martino, G. Sledge, 2012 .

Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, S. Dakhil, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.